Taho Pharmaceuticals (ROCO:6467) Total Assets: NT$455.60 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6467 Taho Pharmaceuticals Ltd ROCO:6467
35 GF Score
Price NT$110.50
! 2 Warning Signs
View Full Analysis

What is Taho Pharmaceuticals Total Assets?

Taho Pharmaceuticals ROCO:6467 -2.64% 35 Total Assets is NT$455.60 Mil as of Dec. 2025. GuruFocus rates ROCO:6467 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Taho Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was NT$455.60 Mil.

During the past 12 months, Taho Pharmaceuticals's average Total Assets Growth Rate was 1.20% per year. During the past 3 years, the average Total Assets Growth Rate was -17.20% per year. During the past 5 years, the average Total Assets Growth Rate was -12.90% per year.

During the past 9 years, Taho Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 5.50%. The lowest was -22.00%. And the median was -9.20%.

Total Assets is connected with ROA %. Taho Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 was -61.87%. Total Assets is also linked to Revenue through Asset Turnover. Taho Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Taho Pharmaceuticals  (ROCO:6467) Total Assets Explanation

Total Assets is connected with ROA %.

Taho Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-285.004/( (465.769+455.595)/ 2 )
=-285.004/460.682
=-61.87 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Taho Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0.631/( (465.769+455.595)/ 2 )
=0.631/460.682
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Taho Pharmaceuticals Total Assets Related Terms

Taho Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Taho Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taho Pharmaceuticals Total Assets Chart

Taho Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only 325.77 199.44 283.20 560.70 455.60

Taho Pharmaceuticals Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 283.20 270.35 560.70 465.77 455.60
ROCO:6467
35GF Score
Taho Pharmaceuticals Ltd ROCO:6467
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taho Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Taho Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=423.697+31.898
=455.60

Taho Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=423.697+31.898
=455.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of NT$455.60 Mil mean?
Taho Pharmaceuticals (ROCO:6467) has a Total Assets of NT$455.60 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Taho Pharmaceuticals and its competitors.
Is Taho Pharmaceuticals' Total Assets too high?
Taho Pharmaceuticals' current Total Assets is NT$455.60 Mil. Overall, Taho Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' Total Assets compare to ZTS and UTHR?
Taho Pharmaceuticals' Total Assets of NT$455.60 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Taho Pharmaceuticals and its competitors. Taho Pharmaceuticals's current Total Assets is NT$455.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current Total Assets of NT$455.60 Mil. The current Total Assets is NT$455.60 Mil. Taho Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current Total Assets is NT$455.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Taho Pharmaceuticals Business Description

Address No. 550, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
35GF Score

Get the complete analysis for ROCO:6467

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$110.50
Price